Lorenzo Nesti

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 13

Top Topics

Glycemic Control

Cardiovascular Disease

Hypertrophic Cardiomyopathy

Top Venues

Cardiovascular diabetology

Diabetes, obesity & metabolism

Obesity (Silver Spring, Md.)

American journal of cardiovascular drugs : drugs, devices, and other interventions

This page only lists publications with an associated author ORCID identifier.

Publications

Martina Chiriacò, Lorenzo Nesti, Allan Flyvbjerg, Alain Golay, Julie-Anne Nazare, Christian Heinz Anderwald, Asimina Mitrakou, Roberto Bizzotto, Andrea Mari, Andrea Natali
At any level of adiposity, relatively elevated leptin concentrations are associated with decreased insulin sensitivity. The Journal of clinical endocrinology and metabolism (2023)
Domenico Tricò, Maria Chiara Masoni, Simona Baldi, Noemi Cimbalo, Luca Sacchetta, Maria Tiziana Scozzaro, Giulia Nesti, Alessandro Mengozzi, Lorenzo Nesti, Martina Chiriacò, Andrea Natali
Early time-restricted carbohydrate consumption vs conventional dieting in type 2 diabetes: a randomised controlled trial. Diabetologia (2023)
Martina Chiriacò, Lorenzo Nesti, Andrea Natali, Nicola Santoro, Sonia Caprio, Domenico Tricò
Proatherogenic changes in lipoprotein particles associated with a high triglyceride to high-density lipoprotein cholesterol ratio in youths. Obesity (Silver Spring, Md.) (2023)
Lorenzo Nesti, Nicola Riccardo Pugliese, Lorenza Santoni, Silvia Armenia, Martina Chiriacò, Luca Sacchetta, Nicolò De Biase, Lavinia Del Punta, Stefano Masi, Domenico Tricò, Andrea Natali
Distinct effects of type 2 diabetes and obesity on cardiopulmonary performance. Diabetes, obesity & metabolism (2023)
Martina Chiriacò, Luca Sacchetta, Giovanna Forotti, Simone Leonetti, Lorenzo Nesti, Stefano Taddei, Andrea Natali, Anna Solini, Domenico Tricò
Prognostic value of 24-hour ambulatory blood pressure patterns in diabetes: A 21-year longitudinal study. Diabetes, obesity & metabolism 24 (11) (2022)
Lorenzo Nesti, Nicola Riccardo Pugliese, Martina Chiriacò, Domenico Tricò, Simona Baldi, Andrea Natali
Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function. Diabetes, obesity & metabolism (2022)
Lorenzo Nesti, Domenico Tricò, Alessandro Mengozzi, Andrea Natali
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovascular diabetology 20 (1) (2021)
Lorenzo Nesti, Nicola Riccardo Pugliese, Paolo Sciuto, Nicolò De Biase, Matteo Mazzola, Iacopo Fabiani, Domenico Trico, Stefano Masi, Andrea Natali
Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes. Cardiovascular diabetology 20 (1) (2021)
Andrea Natali, Lorenzo Nesti, Domenico Tricò, Ele Ferrannini
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovascular diabetology 20 (1) (2021)
Lorenzo Nesti, Alessandro Mengozzi, Andrea Natali
Statins, LDL Cholesterol Control, Cardiovascular Disease Prevention, and Atherosclerosis Progression: A Clinical Perspective. American journal of cardiovascular drugs : drugs, devices, and other interventions 20 (5) (2021)
Lorenzo Nesti, Nicola Riccardo Pugliese, Paolo Sciuto, Andrea Natali
Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach. Cardiovascular diabetology 19 (1) (2020)
Andrea Natali, Lorenzo Nesti, Elena Venturi, Angela C Shore, Faisel Khan, Kunihiko Aizawa, Phillip E Gates, Helen C Looker, Fiona Dove, Isabel Goncalves, Margaretha Persson, Jan Nilsson, null null
Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case-control study. Diabetes, obesity & metabolism 21 (2) (2018)
Andrea Natali, Lorenzo Nesti, Iacopo Fabiani, Enrico Calogero, Vitantonio Di Bello
Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovascular diabetology 16 (1) (2017)